Cristin-person-ID: 576595
Person

Damian Lukasz Szatkowski

  • Stilling:
    Seksjonsoverlege
    ved Medisinsk klinikk ved Helse Førde HF

Resultater Resultater

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Partanen, Anu; Waage, Anders; Peceliunas, Valdas; Schjesvold, Fredrik; Anttila, Pekka; Säily, Marjaana; Uttervall, Katarina; Putkonen, Mervi; Carlson, Kristina; Haukås, Einar mfl.. 2024, Cancers. KAROLINSKA, FINLAND, KYS, TY, OYS, TYKS, PHHYKY, OUS, SVERIGE, OREBRO, SUS, AKADEMISKA, HELSEFØRDE, STOLAV, UIO, HYKS, US LIO, KI, VUVitenskapelig artikkel

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Groen, Kazimierz; Schjesvold, Fredrik Hellem; Van Der Holt, Bronno; Levin, Mark-David; Seefat, Maarten R.; Hansson, Markus; Leys, Maria B.L.; Regelink, Josien C.; Waage, Anders; Szatkowski, Damian Lukasz mfl.. 2023, HemaSphere. RUC, SAHLGREN, OUH, NTNU, OUS, SVERIGE, SUS, RIH, HELSEFØRDE, RH, UIO, NEDERLAND, VUMC, AARHUSSYKE, HBORGVitenskapelig artikkel

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

Zweegman, Sonja; Claudia A M Stege, A; Haukås, Einar; Schjesvold, Fredrik H; Mark-David Levin, Levin; Waage, Anders; Rineke B L Leys, B; Saskia K Klein, K; Szatkowski, Damian Lukasz; Per Axelsson, Axelsson mfl.. 2020, Haematologica. SUS, UvA, SAHLGREN, OUH, STOLAV, HELSEFØRDE, RH, NTNU, UIO, NEDERLAND, AARHUSSYKE, SVERIGEVitenskapelig artikkel

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.

Nielsen, Lene Kongsgaard; Stege, Claudia; Lissenberg-Witte, Birgit I.; van der Holt, Bronno; Mellqvist, Ulf-Henrik; Salomo, Morten; Bos, Gerard; Levin, Mark-David; Visser-Wisselaar, Heleen; Hansson, Markus mfl.. 2019, Haematologica. SAHLGREN, OUH, VUA, LILLEBÆLT, Lu, NTNU, SUS, HELSEFØRDE, STOLAV, RH, UM, EMC, NEDERLAND, VUMCVitenskapelig artikkel

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

Zweegman, Sonja; van der Holt, Bronno; Mellqvist, Ulf-Henrik; Salomo, Morten; Bos, Gerard M.J.; Levin, Mark-David; Visser-Wisselaar, Heleen; Hansson, Markus; van der Velden, Annette W.G.; Deenik, Wendy mfl.. 2016, Blood. SAHLGREN, UMCN, LILLEBÆLT, NTNU, MCA, SUS, ZMC, HELSEFØRDE, STOLAV, RH, UM, EMC, NEDERLAND, VUMC, KIVitenskapelig artikkel
1 - 5 av 7 | Neste | Siste »